Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.

Background: Certain antimitotic drugs have antitumor activities that apparently result from interactions with nontubulin components involved in cell growth and/or apoptotic cell death. Indanocine is a synthetic indanone that has been identified by the National Cancer Institute's Developmental Therap...

Full description

Bibliographic Details
Published in:JNCI: Journal of the National Cancer Institute Vol. 92; no. 3; pp. 217 - 225
Main Authors: Leoni, Lorenzo M., Hamel, Ernest, Genini, Davide, Shih, Hsiencheng, Carrera, Carlos J., Cottam, Howard B., Carson, Dennis A., Leoni, L M, Hamel, E, Genini, D, Shih, H, Carrera, C J, Cottam, H B, Carson, D A
Format: research Journal Article
Published: Oxford University Press / USA 02/02/2000
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=2771986&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 2771986
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00278874
        JNC
      jtl: JNCI: Journal of the National Cancer Institute
      issn: 00278874
      maglogo: N
    pubinfo:
      dt: 02/02/2000
      vid: 92
      iid: 3
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        2771986
        2771986
        NLM10655438
        2771986
        10.1093/jnci/92.3.217
        NLM10655438
        2771986
      ppf: 217
      ppct: 8
      formats:
      tig:
        atl: Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.
      aug:
        au:
          Leoni, Lorenzo M.
          Hamel, Ernest
          Genini, Davide
          Shih, Hsiencheng
          Carrera, Carlos J.
          Cottam, Howard B.
          Carson, Dennis A.
          Leoni, L M
          Hamel, E
          Genini, D
          Shih, H
          Carrera, C J
          Cottam, H B
          Carson, D A
        affil: Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla 92093, USA
      sug:
        subj:
          Hydrocarbons Pharmacodynamics
          Nerve Tissue Proteins Drug Effects
          Drug Resistance
          Neoplasms Drug Therapy
          Cytoplasm Drug Effects
          Drug Resistance, Neoplasm
          Antineoplastic Agents Pharmacodynamics
          Tumor Cells, Cultured
          DNA
          Neoplasms Pathology
          Biochemical Phenomena Drug Effects
          Human
          Nerve Tissue Proteins Metabolism
          Dyes
          Thiazoles
          Peptide Hydrolases Drug Effects
          Flow Cytometry
          Enzymes Drug Effects
          Fluorometry
          Apoptosis Drug Effects
          Fluorescent Antibody Technique
          Heterocyclic Compounds
          Cytoplasm Metabolism
          Proteins
          Neoplasms Metabolism
          Polymers
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
      ab: Background: Certain antimitotic drugs have antitumor activities that apparently result from interactions with nontubulin components involved in cell growth and/or apoptotic cell death. Indanocine is a synthetic indanone that has been identified by the National Cancer Institute's Developmental Therapeutics Program as having antiproliferative activity. In this study, we characterized the activity of this new antimitotic drug toward malignant cells.Methods: We tested antiproliferative activity with an MTT [i.e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay, mitochondrial damage and cell cycle perturbations with flow cytometry, caspase-3 activation with fluorometry, alterations of the cytoskeletal components with immunofluorescence, and antimicrotubule activity with a tubulin polymerization assay.Results/conclusions: Indanocine is a cytostatic and cytotoxic indanone that blocks tubulin polymerization but, unlike other antimitotic agents, induces apoptotic cell death in stationary-phase multidrug-resistant cancer cells at concentrations that do not impair the viability of normal nonproliferating cells. Of the seven multidrug-resistant cell lines tested, three (i.e., MCF-7/ADR, MES-SA/DX5, and HL-60/ADR) were more sensitive to growth inhibition by indanocine than were their corresponding parental cells. Confluent multidrug-resistant cells (MCF-7/ADR), but not drug-sensitive cancer cells (MCF-7) or normal peripheral blood lymphocytes, underwent apoptotic cell death 8-24 hours after exposure to indanocine, as measured by sequential changes in mitochondrial membrane potential, caspase activity, and DNA fragmentation. Indanocine interacts with tubulin at the colchicine-binding site, potently inhibits tubulin polymerization in vitro, and disrupts the mitotic apparatus in dividing cells.Implications: The sensitivity of stationary multidrug-resistant cancer cells to indanocine suggests that indanocine and related indanones be considered as lead compounds for the development of chemotherapeutic strategies for drug-resistant malignancies.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N